A Johns Hopkins University research team has discovered a new family of genes that contributes to the process of malignancy, shedding new light
A Johns Hopkins University research team has discovered a new
family of genes that contributes to the process of malignancy,
shedding new light on the abnormalities that give rise to the aggressive childhood cancer, Burkitt's lymphoma - as well as
lymphoma, leukemia, prostate, ovarian, lung, and breast cancer.
Characterized by rapidly growing abdominal tumors, Burkitt's
lymphoma is one of the three major types of pediatric non-Hodgkin's lymphomas, representing 40% of that group. According to the American Cancer Society, aproximately 57,000 children are
diagnosed with non-Hodgkin's lymphoma per year in the United States, representing about 6% of cancers in children. While aggressive, Burkitt's lymphoma responds well to chemotherapy, and has a 90% survival rate if the tumor has not spread beyond the abdomen.
Scientists have long known that the "myc" family of genes plays a
prominent role in tumor formation, also called neoplastic
transformation. The Hopkins team, focusing on c-myc, found that
another gene called the HMG-I/Y gene is a key genetic "target"
necessary for Myc-mediated transformation.
When the expression of this target gene in Burkitt's lymphoma cell
lines was blocked, the cancer cells revert back to normal-appearing cells. This could point the way to new therapies for one of the most aggressive childhood cancers, as well as other cancers associated with increases in the HMG-I/Y gene according to the Johns Hopkin's research team.
